← Issue №9/ week of Aug 30, 2026/ the whole section, in full

Colorectal, in full.

All 3 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
IBD6Hepatology15Esophagus/Reflux6Pancreas/Biliary5Endoscopy13Motility2Colorectal3Nutrition3
Filter

All 3, in full

most clinically useful first · the 1 the issue led with is ruled in green
Everything here, in one line each3
Colorectal prospective cohort · n=395 · Aug 28, 2026 · Dig Dis Sci · IF 2.5

Validation of a Digital Platform for Colorectal Cancer Risk Stratification and Personalized Screening Recommendations.

New evidenceartificial intelligencecolorectal cancer screeninghealth servicesbiomarker
Clinical takeawayCTC may help identify at-risk individuals and personalize CRC screening recommendations, particularly for higher-risk patients with screening delays (mean 22 years), but further evaluation of patient experience and downstream screening completion is needed before widespread adoption.
What it foundChequeáTuColon (CTC) digital tool showed 100% agreement (κ=1.000) with expert adjudication for CRC risk stratification, alarm symptom detection, genetic evaluation indication, and screening initiation age in a validation study of 395 individuals (median age 59 years).
ContextConfirms that digital risk stratification can match expert judgment, addressing gaps in CRC screening participation and delays, particularly in higher-risk groups.
Refinessuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017

Decision at stakethe use of digital tools for risk stratification and personalized screening recommendations in colorectal cancer screening

Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.

U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗
Casas MA … Pereyra L · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
Colorectal review · Aug 24, 2026 · Gut · IF 24.6

Emerging exposure-driven accelerated colorectal carcinogenesis: a model with implications for screening colonoscopy effectiveness.

Basic sciencebasic scienceepidemiologymicrobiomebiomarker
Clinical takeawayNo clinical action yet: a conceptual model proposing mechanisms for accelerated CRC development, not yet tested in humans.
What it foundProposes a model where environmental and lifestyle exposures accelerate colorectal carcinogenesis, potentially bypassing conventional precursor stages.
ContextChallenges the traditional slow-progression model of CRC, suggesting some cases may arise too rapidly for current screening to prevent.
Emergingsuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017

Decision at stakethe need to consider exposure-driven accelerated carcinogenesis in colorectal cancer screening strategies

Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.

U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗
Truninger K … Fazilaty H · Gut · IF 24.6 · PubMed ↗Permalink
Colorectal rct · n=41 · Aug 27, 2026 · Dis Colon Rectum · IF 3.5

Hypnosis for Postoperative Pain Management Following Colectomies: A Single-Center Randomized Controlled Feasibility Trial.

New evidence
Clinical takeawayNo clinical action yet: a feasibility trial showing signals of benefit, but efficacy requires confirmation in a definitive trial.
What it foundHypnosis reduced median pain scores from 5.0 to 2.5 at 24 hours and from 4.0 to 1.5 at day 3 post-colectomy, with a between-group difference of -1.2 at 24 hours (95% CI -2.3 to -0.1).
ContextPost-colectomy pain management remains opioid-dependent; this is the first RCT to assess hypnosis as an adjunct in this setting.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Toth AM … Alcacer-Pitarch B · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Back to issue №9 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS